Genevoyager focuses on AAV gene therapy and recombinant protein vaccine technology innovation and manufacturing. As an end-to-end CRO/CDMO  service provider, Genevoyager has extensive experience and a proven track record of success in supporting clinical-stage gene therapy and  innovative vaccine programs. Genevoyager is dedicated to accelerate and empower our partners’ efforts to develop safe, effective, and affordable AAV gene therapies and innovative vaccines to address unmet medical needs.